Introduction {#s0005}
============

Ovarian cancers of epithelial derivation are composed of multiple histotypes that differ in commonly mutated genes, clinical course, and presumed cell of origin. Among these histotypes, high-grade serous ovarian cancer (HGSOC), which originates primarily in the fimbrial fallopian tube epithelium (FTE), accounts for the majority of deaths [@bb0005]. The most significant risk factor for HGSOC is a family history of breast or ovarian cancer, with heritable mutations in *breast cancer 1, early onset* (*BRCA1*) or *breast cancer 2, early onset* (*BRCA2*) genes conferring most of this familial risk. Germline *BRCA1* mutation (mt*BRCA1*) carriers have a lifetime HGSOC risk of up to 60% compared to 1.4% to 1.7% for the general female population, whereas germline *BRCA2* mutation (mt*BRCA2*) carriers have a lifetime risk of up to 23% [@bb0010], [@bb0015], [@bb0020]. mt*BRCA1* carriers also tend to be diagnosed at an earlier age than either mt*BRCA2* carriers or sporadic cases [@bb0025], suggesting acceleration of the carcinogenic process by BRCA1 insufficiency.

Additional risk factors for HGSOC are consistent with a promoting role for an increased number of lifetime ovulatory events. The use of oral contraceptives, increased parity, lactation, early menopause, and potentially late menarche reduce risk in the general population [@bb0030], [@bb0035] and in mt*BRCA1* and mt*BRCA2* carriers [@bb0040], [@bb0045]. Ovulation is a recurring event involving a cascade of inflammatory signaling pathways triggered by the LH surge that culminates in the release of the cumulus-oocyte complex and follicular fluid (FF) into the fimbria of the fallopian tube. As a result of the dynamic intrafollicular signaling leading up to ovulation, this periovulatory FF contains cytokines, chemokines, free radicals, and steroid hormones [@bb0050]. Repetitive exposure of the FTE to these FF factors could promote carcinogenesis, perhaps through increased DNA adduct formation and gene mutation to drive development of HGSOC precursors in the distal FTE [@bb0055].

We previously reported that gene expression profiles from nonmalignant FTE from mt*BRCA1* carriers obtained during the postovulatory luteal phase more closely resembled HGSOC than FTE either from control patients or from mt*BRCA1* carriers obtained during the follicular phase [@bb0060]. Further characterization of the molecular differences indicated an increased expression of proinflammatory genes in luteal phase FTE from mt*BRCA1* carriers [@bb0065]. This surprising finding suggested that FTE from mt*BRCA1* carriers might respond differently to ovulation or to the luteal phase milieu.

The primary objective of the current study was to determine whether the response to FF exposure of nonmalignant FTE cells derived from mt*BRCA1* or mt*BRCA2* carriers differs from that of cells derived from control patients. Our findings demonstrate increased inflammatory and epidermal growth factor receptor (EGFR) pathway signaling in FTE from *BRCA1* mutation carriers. We also provide evidence of increased ISGylation, a posttranslational protein modification, in *BRCA1*-deficient cells following exposure to periovulatory FF, raising the possibility that this pathway may contribute to predisposition to HGSOC.

Materials and Methods {#s0010}
=====================

Patient Samples {#s0015}
---------------

Fallopian tube surgical specimens were obtained from 24 women with either known *BRCA1* mutations (*n*=8) or known *BRCA2* mutations (*n*=8), or with no personal or known family history of breast or ovarian cancer (*n*=8). All mt*BRCA1* and mt*BRCA2* carriers underwent risk-reducing salpingo-oophorectomy, whereas control patients underwent surgery for benign conditions ([Table 1](#t0005){ref-type="table"}). The study was approved by Mount Sinai Hospital and Women's College Hospital Research Ethics Boards, and all patients provided informed consent prior to tissue donation.Table 1Age and *BRCA1* and *BRCA2* Mutations for Patients Contributing Surgical Samples for FTE Derivation[a](#tf0005){ref-type="table-fn"}Table 1Patient IDAge (Years)^⁎^Indication for SurgeryMutation Status***BRCA1***150RRSOc.5266dupC238RRSO5083del19349RRSOc.4484G\>T438RRSO3875delGTCT538RRSOc.1994delA641RRSOc.4484G\>T739RRSO5382insC841RRSO185delAG  ***BRCA2***937RRSO3331G\>T1044RRSO6884C\>G1133RRSO5972C\>T1248RRSOc.9435_9436delGT1351RRSOc.517-2A\>G1454RRSO3036delACAA1541RRSOc.5909C\>A1642RRSO9894delT  ***Control***1756Uterine fibroidsN/D1852Uterine fibroidsN/D1954Endometrial hyperplasiaN/D2050Dermatoid cystN/D2133Uterine fibroidsN/D2252Uterine fibroidsN/D2348Uterine fibroidsN/D2447Uterine fibroidsN/D[^4][^5]

Primary FTE Culture {#s0020}
-------------------

Tissue fragments were washed, minced, and incubated for 48 hours in MEM (Invitrogen, Burlington, Canada) containing 1.4 mg/ml Pronase and 0.1 mg/ml DNase I (Roche Diagnostics, Laval, Canada) at 4°C. Enzymes were inactivated by addition of fetal bovine serum (FBS) to 10% (v/v). Dissociated cells were collected; resuspended in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.625μg amphotericin (Invitrogen); and transferred to a positively charged culture plate for 3 to 4 hours. Nonadherent cells were collected and seeded onto collagen type IV--coated Transwell inserts at \>75% confluency, as previously described [@bb0070]. All cultures were maintained with culture medium in both chambers. Medium was replaced every 48 hours until cultures were confluent. Cultures consisted of 49.6%±2.9% (mean±SEM) secretory epithelial cells, 38.0%±2.0% ciliated epithelial cells, and 11.7%±1.6% stromal cells, as determined by immunostaining for Pax8 (ProteinTech, Rosemont, IL), FoxJ1 (Abcam, Cambridge, MA), and vimentin (Dako, Mississauga, Canada), respectively (*n*=4).

OE-E6/E7 Cell Culture {#s0025}
---------------------

OE-E6/E7 cells [@bb0075], obtained from Dr. William S. B. Yeung, University of Hong Kong (China), were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. Short tandem repeat analysis performed for 10 markers verified a human female derivation, and all experiments were conducted within 10 passages from the starting stock culture. A PCR detection kit (Applied Biological Materials Inc., Richmond, BC) was used to test for mycoplasma.

OE-BRCA1 cells were generated by stable transfection with a wild-type *BRCA1* expression construct generated by ligating *BRCA1* cDNA from pcBRCA1-385 (Addgene, Cambridge, MA) into pcDNA3.1H^+^ (Invitrogen). OE-Mock cells were transfected in parallel with empty pcDNA3.1H^+^. Stable transfectants were selected using 80 μg/ml Hygromycin B (Invitrogen).

2-Amino-6-\[2-(cyclopropylmethoxy)-6-hydroxyphenyl\]-4-(4-piperidinyl)-3-pyridinecarbonitrile (ACHP) (Tocris, Minneapolis, MN) was dissolved in DMSO. Cells were treated with 1 to 25 μM in culture medium for 48 hours. Recombinant human IFN-β (R&D, Minneapolis, MN) was reconstituted in water. Cells were treated with 1000 U/ml culture medium.

Ovarian Cancer Cell Lines {#s0030}
-------------------------

SKOV3, ES-2, and HEY ovarian cancer cell lines were grown in RPMI-1640 culture medium supplemented with 5% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. UWB1.289 and UWB1.289 +BRCA1 ovarian cancer cells were grown in a 1:1 ratio of RPMI-1640 with mammary epithelial growth medium (ATCC, Manassas, VA). Medium for UWB1.289 +BRCA1 was further supplemented with G418. All cell lines were verified by STR analysis and tested for mycoplasma as described.

Periovulatory FF Treatment {#s0035}
--------------------------

FF was obtained from the leading follicle from 14 consenting patients undergoing oocyte retrieval as part of their *in vitro* fertilization treatment at Mount Sinai Hospital Fertility Center. The FF samples were subjected to cytokine profiling, which was previously reported [@bb0080], and was pooled and stored at −80°C. Once FTE cultures reached confluency (2-3 weeks), culture medium in the upper Transwell chamber was replaced with 100 μl filter-sterilized FF for 24 hours followed by replacement with fresh culture medium. Paired baseline cultures were treated in parallel, except culture medium was used instead of FF. The lower chamber contained culture medium alone for all cultures. See [Figure 1](#f0005){ref-type="fig"} for treatment schematic. Exposure of FTE cells to undiluted FF increases rather than decreases cell number [@bb0085] ([Supplementary Figure S1](#f0040){ref-type="graphic"}), indicating that this treatment was not toxic to cells.

Gene Expression Profiling and Analysis {#s0040}
--------------------------------------

RNA was extracted from primary FTE cultures using TRIzol (Invitrogen), further purified using an RNeasy MiniElute cleanup kit (Qiagen, Toronto, Canada), and quantified by NanoDrop spectrophotometry. All samples had a minimum RNA integrity value of 8.0 (Agilent bioanalyzer system). Whole genome transcriptome profiling was performed at the Princess Margaret Genomics Centre. RNA (200 ng) was labeled using Illumina TotalPrep-96 RNA amplification kit (Thermo Fisher Scientific, Burlington, Canada), and 750 ng of resulting cDNA was hybridized onto Illumina Human HT-12 v4.0 Beadchip Arrays. The beadchips were washed and stained per Illumina protocol and scanned on an iScan (Illumina) scanner. Gene expression profiling data are available at NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo, accession number GSE98699).Figure 1Schematic showing the treatment paradigm. Dissociated fallopian tube epithelial cells were seeded into the upper chamber of 24-well Transwells coated with collagen IV and grown to confluence **(**A). Follicular fluid (FF) was added to the upper chamber and was replaced with culture medium after 24 hours (B**)**. Cells were harvested 24 hours after FF addition (F24) or 24 hours after replacing FF with culture medium (FC). Parallel cultures from each patient were treated similarly except that culture medium was used instead of FF (C24 and C48).Figure 1

Microarray data were converted to log2 and quantile median-normalized using Genespring v12.1 software. Samples were run in two balanced batches due to the interval in collecting patient derived material; therefore, a further batch effect normalization was performed using CombatR [@bb0090]. Unsupervised hierarchical clustering using average linkage rules and Pearson-centered metrics was performed to assess the overall degree of gene expression similarity among samples. All probes were filtered prior to analysis to remove probes showing no signal across all three sample groups (80% of samples in either group having expression in the 20th to 100th percentile of measured signal values). A one-way ANOVA with a TUKEY HSD using Benjamini-Hochberg false discovery rate (FDR) for each comparison was used to identify probes whose mean expression was different between genotypes at each time point.

Gene Ontology (GO) analysis was performed on genes significantly different with a 1.5-fold change cutoff between mt*BRCA1* or mt*BRCA2* and control samples at the three time points using an FDR \<0.3. GSEA was performed between patient groups at the three time points using GSEA software version 2.2.2 and predefined gene sets from the Molecular Signatures Database (MSigDB v5.0). Analysis between patient groups at the three time points involved 1000 permutations using the signal2noise metric. Gene sets with an FDR \<0.25 were identified and interactions between gene sets were visualized with Cytoscape software [@bb0095].

Quantitative Real-Time RT-PCR (RT-qPCR) {#s0045}
---------------------------------------

RNA was extracted from OE-E6/E7 cells with an RNeasy Plus Universal Mini Kit (Qiagen), and transcript levels for *IL8, TNF, HRAS, ISG15, HERC5*, *USP18* in OE-Mock and OE-BRCA1 cells were measured by RT-qPCR using primers shown in [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}. RNA was reverse transcribed using Superscript III and random hexamers (Invitrogen). qPCR was performed using an ABI PRISM 7900HT sequence detection system (Invitrogen) with SYBR Green PCR Master Mix (Invitrogen) and analyzed using the ΔCCT method. Target gene C~T~ were normalized to the geometric mean of three housekeeping genes, *GAPDH*, *YWHAZ*, and *B2M*, using standard curves. Data are expressed as mean±SEM.

Western Blot Analysis {#s0050}
---------------------

Cellular proteins were extracted using RIPA lysis buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate) containing protease and phosphatase inhibitors (Roche Diagnostics) and quantified using BCA Protein Assay Kit (Thermo Fisher Scientific). Protein extracts were resolved by SDS-PAGE, transferred to PVDF membranes, and immunoblotted with anti-BRCA1 (1:500; sc-6954, Santa Cruz Biotechnology, Dallas, TX), anti-ISG15 (1:2000, a gift from Dr. Arthur Haas, Louisiana State University) [@bb0100], anti-EGFR (1:1000, \#2232), anti-pERK1/2 (1:2000, \#9101), anti-ERK1/2 (1:2000, \#4696), anti-USP18 (1:1000, \#4813) (Cell Signaling Technology, Danvers, MA), anti-tubulin (1:3000, \#T6199, Sigma), or anti-HSP90 (1:5000, \#610418, BD Transduction Laboratories, Mississauga, Canada) antibodies. Immunoblots were then incubated with horseradish peroxidase--conjugated goat anti-rabbit (1:1000, sc-2004, Santa Cruz Biotechnology) or horse anti-mouse antibodies (1:1000, \#7076, Cell Signaling Technology). Immunoreactive bands were visualized by enhanced chemiluminescence (Santa Cruz Biotechnology) and quantified using ImageJ software.

Statistical Analysis {#s0055}
--------------------

RT-qPCR and Western blot data were analyzed by one-sample *t* test, one-way ANOVA followed by a Student-Neuman-Keuls (SNK) *post hoc* test, or two-way ANOVA (Prism 5). Comparisons were considered statistically significant at *P*\<.05.

Results {#s0060}
=======

mt*BRCA* Status and FF Exposure Alter Gene Expression Profiles {#s0065}
--------------------------------------------------------------

Primary FTE cell cultures derived from mt*BRCA1* or mt*BRCA2* carriers or control patients were grown on collagen IV--coated tissue culture Transwells to simulate *in vivo* FTE structure [@bb0070]. Periovulatory human FF was added to the upper chamber for 24 hours to simulate transient apical FTE ovulatory exposure *in vivo*. Genome-wide gene expression profiles were obtained 24 hours after FF addition (*t*=F24, acute response) and 24 hours after its replacement with culture medium (*t*=FC, recovery). Paired baseline (*t*=C24 and C48) cultures were treated in parallel, except that culture medium was used instead of FF ([Figure 1](#f0005){ref-type="fig"}). Since analysis indicated no differences in gene expression between baseline cultures collected at 24 and 48 hours, only baseline data obtained at 24 hours (C24) were included in further analysis.

Unsupervised hierarchical clustering of all 72 culture samples (24 patients × 3 time points) based upon overall gene expression resulted in all three time point samples (C24, F24, FC) from each patient clustering most closely together for 20 of the 24 patients ([Figure 2](#f0010){ref-type="fig"}*A*). While this pattern largely reflects patient variation, an impact of mt*BRCA* status was indicated. The 72 samples partitioned into 3 main clusters, with mt*BRCA1* samples dominating one cluster (Group 1A; 67% of mt*BRCA1*, 33% of mt*BRCA2*, and 4% control). A second and smaller cluster (Group 1B) contained no mt*BRCA1*, 25% of mt*BRCA2*, and 12.5% of control patient samples, whereas the third and largest cluster was dominated by control patient samples (Group 2; 83% of control, 33% of mt*BRCA1*, and 42% of mt*BRCA2*). Samples did not partition based upon FF exposure, indicating that mt*BRCA* status had a greater impact on overall gene expression than FF.Figure 2Hierarchical clustering of FTE samples based on gene expression profiles indicates an impact of BRCA1 and BRCA2 mutation status and FF exposure. **(**A) Dendrogram resulting from unsupervised hierarchical clustering of all culture samples based upon expression of all filtered gene probesets. (B**)** Hierarchical clustering of all culture samples based upon expression of 4218 gene probesets identified as significantly different by one-way ANOVA. mt*BRCA1* samples are coded in red, mt*BRCA2* samples are coded in blue, and control patient culture samples are coded in green. Sample identification numbers correspond to patient numbers shown in [Table 1](#t0005){ref-type="table"}.Figure 2

One-way analysis of variance identified 4218 probesets with differential expression between all 9 groups (3 genotypes × 3 timepoints). Clustering of samples based upon these genes revealed three principal groupings, with mt*BRCA1* samples largely partitioning separately (Group 1) from control patient samples (Group 2B), and mt*BRCA2* samples distributed evenly within the groupings ([Figure 2](#f0010){ref-type="fig"}*B*). While this pattern further indicates that mutation status has the greatest impact on gene expression, an impact of FF exposure was also evident, as 83% of F24 samples partitioned away from their matched baseline sample. Moreover, a subgroup of F24 samples from all three patient categories clustered together in Group 2A (3 control, 4 mt*BRCA1*, 5 mt*BRCA2*).

Differentially Expressed Genes Based Upon mt*BRCA* Status Are Affected by FF Exposure {#s0070}
-------------------------------------------------------------------------------------

The overlap in genes differentially expressed based on mt*BRCA* status at baseline (C24) and after FF exposure (F24 and FC) is shown in [Figure 3](#f0015){ref-type="fig"}. A greater number of probesets were differentially expressed between mt*BRCA1* versus control patient samples at all time points, as compared to mt*BRCA2* versus controls. At baseline, 831 probesets were differentially expressed in mt*BRCA1* samples, and 460 probesets were differentially expressed in mt*BRCA2* samples, as compared to control patient samples. With acute FF exposure (F24), the number of differentially expressed probesets decreased (615 for mt*BRCA1* and 111 for mt*BRCA2*), and this number increased upon recovery from FF exposure (FC) to 1198 for mt*BRCA1* and 337 for mt*BRCA2*. Approximately half of the genes differentially expressed in mt*BRCA2* samples versus control patient samples were also differentially expressed in mt*BRCA1* samples versus control patient samples ([Figure 3](#f0015){ref-type="fig"}).Figure 3mt*BRCA1* samples have a greater number of significantly different genes than mt*BRCA2* samples relative to control FTE at all time points. Overlap of statistically significant differentially expressed gene probesets in mt*BRCA1* and mt*BRCA2* samples relative to control patient samples is shown (A) at baseline (C24), (B) after 24hours of FF exposure (F24), and (C) after 24 hours of recovery following FF exposure (FC). Numbers provided are the number of probesets significantly different based upon one-way ANOVA (*P*\<.05). The number of genes with increased expression in BRCA mutants versus control is in the left column, and that with decreased expression in BRCA mutants versus control is in the right column.Figure 3

At FC, there were 44% more probesets differentially expressed between mt*BRCA1* and control patients than at baseline (1198 vs 831) ([Figure 3](#f0015){ref-type="fig"}), whereas the number of differentially expressed genes in mt*BRCA2* samples was decreased by 27% (337 vs 460). Moreover, no more than 50% of gene probesets identified as differentially expressed at FC overlapped with either C24 or F24 for mt*BRCA1* or mt*BRCA2* samples ([Supplementary Figure S2](#f0045){ref-type="graphic"}). This suggests a delayed differential response to FF exposure based on mt*BRCA* status.

mt*BRCA1* Status Impacts Immune and EGFR Signaling Pathway-Associated Genes {#s0075}
---------------------------------------------------------------------------

To derive a functional profile of differentially expressed genes at each time point, GO analyses were performed on genes significantly different with a 1.5-fold change cutoff between mt*BRCA1* or mt*BRCA2* and control samples. At baseline, genes increased and decreased in mt*BRCA1* samples associated with 17 and 20 GO terms, respectively ([Supplementary Table S2](#ec0010){ref-type="supplementary-material"}). No GO terms associated with genes increased at F24 in mt*BRCA1*, whereas 7 GO terms associated with decreased genes. At FC, 7 GO terms associated with genes increased in mt*BRCA1*, and 21 GO terms associated with decreased genes.

GO terms identified at all three time points were primarily associated with inflammation and immune system: altogether, 61.4% (27 of 44) of the significant GO terms for mt*BRCA1* samples were related to the immune system. This suggests that most gene expression changes due to mt*BRCA1* status alone and to FF exposure involve alterations in immune response or cytokine signaling. Additionally, GO terms relating to proliferation, apoptosis, and cell-cell junction were associated with genes increased in mt*BRCA1* at baseline. New GO terms emerging at FC included response to virus, innate immune response, and activation of immune response ([Supplementary Table S2](#ec0010){ref-type="supplementary-material"}). In contrast, no GO terms associated with mt*BRCA2* differentially expressed genes either at baseline or FC. At F24, five GO terms were associated with decreased genes in mt*BRCA2* samples that were related to immune system response and function ([Supplementary Table S3](#ec0015){ref-type="supplementary-material"}).

As opposed to GO analysis, GSEA is a multivariate tool that takes into account all changes in gene expression to identify multiple pathway members that collectively could amount to a larger impact on particular cell functions. GSEA was performed between all mt*BRCA* status groups at baseline, F24, and FC. Only comparisons between mt*BRCA1* versus control patients provided genesets with an FDR \<0.25. A total of 246 genesets were upregulated in mt*BRCA1* versus control at baseline, while no genesets attained significance as downregulated. Many of these upregulated genesets are involved in inflammation, DNA damage, and growth pathways ([Supplementary Table S4](#ec0020){ref-type="supplementary-material"}). Visualization of enriched geneset networks using Cytoscape revealed two large clusters: NFκB-related and EGFR-related pathways ([Figure 4](#f0020){ref-type="fig"}*A*). At F24, the only geneset with an FDR \<0.25 for mt*BRCA1* versus control was "Reactome pyruvate metabolism," which was decreased in mt*BRCA1* samples.

Αt FC, 182 genesets were associated with upregulated genes in mt*BRCA1* relative to control patient samples ([Supplementary Table S5](#ec0025){ref-type="supplementary-material"}). Visualization revealed a large cluster of linked genesets involved with interferon signaling ([Figure 4](#f0020){ref-type="fig"}*B*). Genes forming the leading-edge subset within genesets represent those that contribute most to the enrichment score and have the largest fold-change in expression. The leading-edge gene subset of the top 20 genesets between mt*BRCA1* and control at FC, based upon the normalized enrichment score, is shown in [Table 2](#t0010){ref-type="table"}. Among these, *ISG15* and some of its key interacting partners involved in ISGylation (*HERC5*, *HERC6* and *USP18*) were upregulated in mt*BRCA1* versus control samples. In fact, *ISG15* expression was 4.5-fold higher in mt*BRCA1* versus control samples and appears in 14 of the top 20 genesets at FC. Moreover, *ISG15* was upregulated 3.4-fold at baseline in mt*BRCA1* versus control samples.

Altering BRCA1 Levels Replicates Key Differences in Gene Expression {#s0080}
-------------------------------------------------------------------

OE-E6/E7 immortalized human FTE cells were used to address whether changes in gene expression reflect BRCA1 levels as opposed to differential programming of the primary FTE cells *in vivo*. OE-E6/E7 cells express low levels of BRCA1 relative to HEY, ES2, and SKOV3 ovarian cancer cell lines ([Figure 5](#f0025){ref-type="fig"}*A*). Therefore, OE-E6/E7 cells were stably transfected with wild-type *BRCA1* (OE-BRCA1) or transfected with empty expression vector (OE-Mock), resulting in cells expressing high and low BRCA1 levels, respectively ([Figure 5](#f0025){ref-type="fig"}*A*). *TNFα*, *IL8*, *ISG15*, and *HRAS* were found to have increased expression in mt*BRCA1* samples at baseline and were selected for investigation. Consistent with our primary FTE gene expression profiles, *TNFα, IL8,* and *ISG15* transcript levels were suppressed by increased BRCA1 levels in OE-E6/E7 cells ([Figure 5](#f0025){ref-type="fig"}, *B*-*D*), whereas increased BRCA1 did not alter *HRAS* transcript levels ([Figure 5](#f0025){ref-type="fig"}*E*).Figure 4GSEA of gene expression profiles from mt*BRCA1* samples compared to control patient samples reveals three major gene clusters. **(**A) Cytoscape visualization of gene networks increased in mt*BRCA1* samples versus control patient samples at baseline (C24) showing two main clusters indicating altered NFκB and EGFR signaling. (B) Cytoscape visualization of gene networks increased in mt*BRCA1* samples versus control patient samples after 24 hours of recovery from FF exposure (FC) showing one main cluster of significant gene sets in mt*BRCA1*, which reflect altered interferon responsive genes. The size of the node reflects the number of genes within the geneset. Red nodes represent increased expression of the genes within the geneset in mt*BRCA1* versus control. Edge thickness reflects the number of genes that overlap between connected genesets. All GSEAs were performed using an FDR \<0.25.Figure 4Figure 5Increased BRCA1 expression inhibits expression of NFκB target genes and alters the impact of FF exposure on expression of ISG15 and its interacting partners. (A) Left: Representative Western blot showing BRCA1 protein levels in OE-E6/E7 cells compared to ovarian cancer cell lines. UWB1.289 and UWB1.289+BRCA1 cells were used as a negative and positive control respectively. Right: Representative Western blot and comparison of BRCA1 levels in OE-Mock and OE-BRCA1 cells. Levels of HSP90 are shown as a loading control. Bars represent the mean ± SEM of three independent experiments relative to levels measured in OE-BRCA1 cells. \**P*=.0075, one-sample *t* test. (B-E) Comparison of TNFα (B), IL8 (C), ISG15 (D), and HRAS (E) transcript levels in OE-Mock and OE-BRCA1 cells as determined by RT-qPCR. Bars represent the mean ± SEM of three independent experiments relative to levels measured in OE-Mock cells. \**P*\<.05, one-sample *t* test. (F-H) Comparison of ISG15 (F), HERC5 (G), and USP18 (H**)** transcript levels in OE-Mock and OE-BRCA1 at baseline (C24), after 24 hours of FF exposure (F24), and 24 hours after recovery from FF exposure (FC). Bars represent the mean ± SEM of three (for HERC5 and USP18) or four (for ISG15) independent experiments relative to levels measured in OE-Mock cells at C24. Bars with different letters are statistically different from one another as determined by one-way ANOVA followed by SNK *post hoc* test.Figure 5Table 2Significantly Upregulated Genes from the Leading Edge Subset of the Top 20 Gene Sets from the GSEA Comparing mt*BRCA1* and Control after Recovery from Follicular Fluid Exposure (FC)Table 2*Gene SymbolFold Change\# of Gene Sets Within Top 20Gene SymbolFold Change\# of Gene Sets Within Top 20*IFIT16.3813FAM46A1.861OAS24.9510USP181.844ISG154.5014PLAUR1.801IFIT33.6912SP1101.785MX13.6213IFIH11.786CXCL103.415DDX581.777IFI44L3.307ITGB81.751IRF73.1012DDX601.697MX22.987PAFAH1B31.631RSAD22.975EIF2AK21.625OAS32.958PARP121.615OAS12.9110TSPAN11.601IFI442.908TAP11.582HERC62.836LAMP31.543EPSTI12.783ARTN1.481HS3ST12.721PARP141.462HERC52.356ATP6V1F1.451OASL2.2910YWHAB1.453HLA-C2.291PARP101.441SAMD9L2.273CMPK21.433IFIT22.265IRF31.373IFI352.2111ZBP11.334XAF12.158IFIT51.304PRIC2852.102RIPK31.301PARP92.073DHX581.293STAT12.069NAGK1.281DDX60L1.981RTEL11.261SAMD91.965HRAS1.111

GSEA also indicated that FF treatment of primary FTE cultures transiently suppressed interferon-induced gene expression that was otherwise elevated in mt*BRCA1* samples at other time points. These genes included multiple regulators of the ISG15 protein modification pathway, including *HERC5* and *USP18*. To determine whether these differences could be due to differential BRCA1 levels, OE-Mock and OE-BRCA1 cells were treated with FF in a manner identical to the primary FTE cultures. At baseline and FC, levels of *ISG15, HERC5*, and *USP18* transcripts were significantly greater in OE-Mock compared to OE-BRCA1 cells ([Figure 5](#f0025){ref-type="fig"}, *F*-*H*), indicating that high levels of BRCA1 suppress their expression. Treatment of OE-Mock cells with FF (F24) suppressed levels of all three transcripts to those measured in OE-BRCA1 cells at baseline.

The impact of BRCA1 expression on USP18 and conjugated and free ISG15 protein levels in OE-E6/E7 cells was investigated. Since expression of these genes is activated by type I interferon, protein levels were examined 24 hours after IFNβ or vehicle treatment. In vehicle-treated cells, increased BRCA1 decreased both free ISG15 ([Figure 6](#f0030){ref-type="fig"}, *A* and *B*) and USP18 ([Figure 6](#f0030){ref-type="fig"}, *D* and *E*), which is consistent with our findings on transcript levels. As expected, similar levels of both proteins in OE-Mock and OE-BRCA1 cells were measured after IFNβ treatment ([Figure 6](#f0030){ref-type="fig"}, *B* and *F*). Conjugated ISG15 levels were also increased in OE-Mock relative to OE-BRCA1 cells, and this difference persisted with IFNβ treatment ([Figure 6](#f0030){ref-type="fig"}*C*).Figure 6Increased BRCA1 expression inhibits ISGylation and decreases ISG15, USP18, and EGFR protein levels. (A) Representative Western blot showing free and conjugated ISG15 levels in OE-Mock and OE-BRCA1 cells in the presence and absence of 24-hour treatment with 1000 U/ml IFNβ. Levels of HSP90 are shown as a loading control. LE=long exposure; SE=short exposure. (B and C) Comparison of free ISG15 (B) and ISG15 conjugates (C) in OE-Mock and OE-BRCA1 cells in the presence or absence of IFNβ treatment. Bars represent the mean ± SEM of six independent experiments relative to levels measured in vehicle-treated OE-Mock cells. \**P*\<.05; \*\**P*\<.01; \*\*\**P*\<.001, *t* test. (D) Representative Western blot showing USP18 levels in OE-Mock and OE-BRCA1 cells in the presence and absence of 24-hour treatment with 1000 U/ml IFNβ. (E and F) Comparison of USP18 levels on OE-Mock and OE-BRCA1 cells in the absence (E) or presence (F) of IFNβ treatment. Bars represent the mean ± SEM of three independent experiments relative to levels measured in OE-Mock cells. Levels of USP18 following IFNβ treatment were determined on short exposure blots. \**P*\<.001, one-sample *t* test. (G) Representative Western blot showing levels of EGFR in OE-Mock and OE-BRCA1 cells. (H) Comparison of EGFR levels normalized to HSP90. Bars represent the mean ± SEM of four independent experiments relative to levels measured in OE-Mock cells. \**P*\<.02, one-sample *t* test.Figure 6

Although EGFR mRNA was not increased in mt*BRCA1* primary FTE cultures, GSEA indicated upregulation of EGFR signaling associated with lower levels of functional BRCA1. Consistent with this inverse relationship, increased BRCA1 expression in OE-E6/E7 cells decreased EGFR protein levels ([Figure 6](#f0030){ref-type="fig"}*G* and *H*).

Increased NFκB Signaling in Cells with Low BRCA1 Levels Increases ISG15, EGFR, and pERK1/2 {#s0085}
------------------------------------------------------------------------------------------

To investigate whether elevations in ISG15 and EGFR due to decreased BRCA1 levels are mediated through NFκB signaling, OE-Mock and OE-BRCA1 cells were treated with increasing doses of the IKKα/β inhibitor ACHP. Consistent with our findings above, free and conjugated ISG15 ([Figure 7](#f0035){ref-type="fig"}, *A*-*C*) and EGFR ([Figure 7](#f0035){ref-type="fig"}, *D* and *E*) levels were increased in OE-Mock cells relative to OE-BRCA1 cells. pERK1/2 levels, a downstream EGFR mediator, were also increased in OE-Mock cells ([Figure 7](#f0035){ref-type="fig"}, *F*-*H*). ACHP treatment decreased both free and conjugated ISG15 in OE-Mock cells to levels comparable to those in vehicle-treated OE-BRCA1 cells, whereas ACHP treatment did not alter ISG15 levels in OE-BRCA1 cells. Similarly, high (10 and 25 μM) ACHP decreased EGFR protein levels in OE-Mock but not OE-BRCA1 cells. In contrast, pERK1/2 levels were reduced at high doses of ACHP similarly in both OE-Mock and OE-BRCA1 cells. This suggests that elevated ISG15, EGFR, and ERK1/2 activation levels observed in low BRCA1-expressing cells are due to increased NFκB signaling.Figure 7Increased NFκB activity in BRCA1-deficient cells leads to increased ISG15 and may contribute to increased EGFR signaling. (A) Representative Western blot showing levels of free and conjugated ISG15 in OE-Mock and OE-BRCA1 cells following inhibition of NFκB signaling by increasing doses of ACHP for 48 hours. Levels of HSP90 are shown as a loading control. LE=long exposure; SE=short exposure. (B and C) Comparison of free (B) and conjugated ISG15 (C) levels normalized to HSP90. Bars represent the mean ± SEM of four independent experiments relative to levels measured in vehicle-treated OE-Mock cells. Two-way ANOVA indicated a significant effect of BRCA1 expression (*P*\<.0001), ACHP treatment (*P*\<.0001), and interaction (*P*\<.0001, free; *P*\<.002, conjugated). The effect of ACHP treatment was analyzed separately for OE-Mock and for OE-BRCA1 cells by one-way ANOVA followed by SNK *post hoc* test. Bars with different letters within each cell subline are statistically different from one another. (D) Representative Western blot showing levels of EGFR in OE-Mock and OE-BRCA1 cells following ACHP treatment. (E) Comparison of EGFR levels normalized to HSP90 in four independent experiments. Levels are relative to vehicle-treated OE-Mock cells. Two-way ANOVA indicated a significant effect of BRCA1 expression (*P*\<.002) and ACHP treatment (*P*\<.0001), but not interaction. The effect of ACHP treatment was analyzed separately for OE-Mock and for OEBRCA1 cells by one-way ANOVA followed by SNK *post hoc* test. (F) Representative Western blot showing levels of pERK1/2 in OE-Mock and OE-BRCA1 cells following ACHP treatment. (G and H) Comparison of pERK1 (G) and pERK2 (H) levels normalized to total ERK1 or total ERK2 levels in four independent experiments. Levels are relative to vehicle-treated OE-Mock cells. Two-way ANOVA indicated a significant effect of BRCA1 expression (*P*\<.0001) and ACHP treatment (*P*\<.002, pERK1; *P*\<.0002, pERK2), but no interaction. The effect of ACHP treatment was analyzed separately for OE-Mock and for OE-BRCA1 cells by one-way ANOVA followed by SNK *post hoc* test. (I) Schematic model for the impact of BRCA1 expression on suppression of inflammatory signaling and ISGylation. ISGylation targets multiple proteins including the EGFR and several members of the downstream MAPK signaling cascade.Figure 7

Discussion {#s0090}
==========

This study demonstrates that FTE cells from mt*BRCA1* carriers have a gene expression profile that is distinct from that of FTE from control patients. Even in the absence of FF exposure, mt*BRCA1* samples displayed molecular profiles indicative of increased inflammatory and EGFR signaling. Moreover, following recovery from FF exposure, an increased expression of type I interferon-responsive genes, including multiple members of the ISGylation protein modification pathway, was apparent in mt*BRCA1* samples.

Numerous genes were also differentially expressed in mt*BRCA2* samples compared to control patient samples. However, GSEA failed to identify statistically significant genesets. It is interesting to note that the top ranking genesets in mt*BRCA2* versus control samples were similar to those significantly elevated in mt*BRCA1* versus control samples, particularly after recovery from FF exposure. These were characterized by elevated interferon target genes ([Supplementary Table S6](#ec0030){ref-type="supplementary-material"}, [Supplementary Table S7](#ec0035){ref-type="supplementary-material"}). Previous studies have shown increased interferon target gene expression in *BRCA2*-null colorectal carcinoma cells [@bb0105] and that BRCA2 binds the transcriptional repressor EMSY to suppress interferon gene expression [@bb0110]. Further studies are required to investigate the impact of *BRCA2* mutations on interferon target gene expression and inflammatory signaling.

Chronic inflammatory signaling, which is mediated by NFκB, is associated with precipitating events in carcinogenesis and is activated in nearly all cancers [@bb0115]. Key NFκB target genes, including *TNFα*, *IL8*, and *ISG15,* were increased in mt*BRCA1* FTE compared to that derived from control patients. Expression of BRCA1 in OE-E6/E7 cells decreased the levels of these transcripts, indicating that this is a direct result of decreased functional BRCA1. TNFα and IL8 promote leukocyte recruitment, and TNFα is a potent activator of further NFκB signaling. Thus, increased expression of these cytokines would likely increase local inflammatory signaling *in vivo*. An increase in IL8 expression following FF exposure in non--BRCA1-deficient bovine and human oviductal cells was shown by us and others [@bb0080], [@bb0085]. Notably, *BRCA1*-mutated luteal phase FTE grouping with HGSOC in our previous study showed increased *IL8* expression, in addition to other monocyte/neutrophil chemokines [@bb0060].

We previously demonstrated that decreasing BRCA1 expression in ES2 ovarian and A549 lung cancer cells enhanced NFκB signaling [@bb0065], but the precise mechanism involved is not clear. Sau et al. [@bb0120] similarly found increased NFκB signaling in BRCA1-deficient mammary gland progenitor cells, which they attributed to the DNA damage response. However, BRCA1 binds RelA/p65 and p50 and may act as a co-activator to promote canonical NFκB signaling [@bb0125]; thus, further studies are required to define the precise mechanisms by which BRCA1 deficiency leads to increased NFκB signaling.

An inverse relationship between BRCA1 and EGFR has been identified in both breast and ovarian cancer [@bb0130], [@bb0135]. This is consistent with our finding of increased EGFR target gene expression in mt*BRCA1* samples and a decrease in EGFR levels in OE-E6/E7 cells expressing increased wild-type BRCA1 levels. Inhibition of IKKα/β by ACHP reduced EGFR protein expression in both OE-Mock and OE-BRCA1 cells, indicating that EGFR signaling is downstream of NFκB. Since EGFR also activates NFκB signaling [@bb0140], this could lead to a positive feed-forward cycle between EGFR and NFκB in BRCA1-deficient cells.

Cross-talk between NFκB and EGFR signaling has been previously demonstrated by others. NFκB regulated KIAA1199/CEMIP was shown to increase EGFR signaling by reducing EGFR lysosome-dependent degradation in cervical and breast cancer cells [@bb0145]. Also, knockdown of IKKα and IKKβ suppressed EGFR signaling in head and neck cancer cells [@bb0150]. EGFR has also been shown to activate NFκB signaling either directly or indirectly through JAK/STAT signaling, leading to a positive feed-forward cycle between EGFR and NFκB [@bb0140], [@bb0155], [@bb0160], [@bb0165]. Elevation of EGFR signaling pathways is involved in cell survival and growth. While activating mutations in downstream EGFR targets such as *RAS* and *ERK* are typically associated with low-grade serous ovarian carcinoma, EGFR amplification and overexpression in HGSOC have been reported [@bb0170].

Previous studies have indicated increased expression of type I interferon target genes in *BRCA1-* and *BRCA2*-deficient cells relative to controls in multiple cell types, including breast and HGSOC cells [@bb0105], [@bb0175]; however, this increase did not fully emerge in our nonmalignant primary FTE cell cultures until after FF exposure. Increased *ISG15* transcripts were identified in mt*BRCA1* compared to control samples at both baseline and after recovery from FF exposure. *ISG15* expression is increased in many epithelial cancers [@bb0180], [@bb0185], [@bb0190] and contributes to RAS-induced oncogenic transformation of breast epithelial cells [@bb0195].

ISG15 functions in protein modification and as a mature free protein. While free ISG15 is found intracellularly, it is also secreted and acts upon lymphocytes to induce release of IFNγ and possibly other cytokines [@bb0200]. Secreted ISG15 was shown to suppress tumor growth, increase natural killer cell tumor infiltration, and enhance cell surface MHC class I expression in breast tumors [@bb0205]. Thus, free ISG15 may have a different impact on cancer progression than increased ISGylation. BRCA1 expression in OE-E6/E7 cells decreased both free ISG15 and ISGylated protein levels. This suggests that BRCA1 deficiency directly results in increased *ISG15* expression and demonstrates a functional impact of the altered transcript levels. Several ISG15 E3 ligases have been identified that determine substrate specificity for ISGylation. Among these, HERC5, which was upregulated in OE-Mock versus OE-BRCA1 cells and in mt*BRCA1* versus control samples after FF recovery, is the most common and has a wide range of target proteins [@bb0210].

ISGylation has been implicated in cancer development and progression. Desai et al. [@bb0215] demonstrated that ISGylation disrupts F-actin architecture and formation of focal adhesions, and promotes migration in breast cancer cells. Induction of ISGylation in mice exacerbates intestinal inflammation, increases ROS, and promotes generation of colitis-associated colon cancer [@bb0220]. ISG15 protein expression is increased in relapsed HGSOCs compared to primary tumors [@bb0225]. As well, 20% of ovarian cancer cases express an "interferon-related" gene signature that includes ISG15 [@bb0230]. Over 150 ISGylated proteins have been identified [@bb0235]; however, the impact of ISGylation on function has only been investigated for a limited number of targets.

ISG15 expression is upregulated by TNFα [@bb0240] and has dual effects on NFκB signaling [@bb0245], [@bb0250]. We demonstrated that blocking NFκB activation decreased ISG15 expression and overall ISGylation in OE-Mock cells to levels measured in OE-BRCA1 cells, indicating that BRCA1 deficiency increases ISG15 levels through increased NFκB signaling. ERK1 has been identified as an ISGylation target [@bb0255], and we found increased ERK1/2 activation associated with decreased BRCA1 expression. Further studies are required to determine if ISGylation is involved in the impact of BRCA1 deficiency on ERK1/2 activation as inhibitors to this protein modification pathway are currently unavailable.

ISGylation is reversible through the deconjugating activity of USP18 [@bb0260], [@bb0265]. *USP18* transcripts were not increased in mt*BRCA1* samples at baseline and emerged as significantly elevated only after FF exposure, when *HERC5* transcripts were also elevated. Increased BRCA1 levels in OE-E6/E7 cells decreased *ISG15, HERC5*, and *USP18* transcripts; however, unlike the primary cultures, this impact on *HERC5* and *USP18* was detected at baseline. FF exposure transiently suppressed transcript levels of all three genes in OE-Mock cells to levels similar to those measured in OE-BRCA1 cells, which were unaffected by FF. The variation in overall gene expression between patients could have prevented the interferon gene expression signal reaching statistical significance at baseline in the primary cultures. Alternatively, expression of *ISG15* interacting partners may vary at baseline but has a concerted response to FF exposure and recovery. It is interesting to note that increased USP18 expression did not prevent the increase in ISGylated protein levels. However, USP18 has independent direct effects on tumor growth and survival and enhances EGFR signaling by decreasing miR-7 expression, which targets EGFR [@bb0270]. Thus, USP18 may contribute to increased EGFR signaling.

While we had expected the combination of FF and *BRCA1* mutation would globally increase proinflammatory signaling, FF exposure appeared to transiently suppress several inflammatory genes in mt*BRCA1* cells to the level of controls. Steroid hormones, which are found at high levels in FF, have been shown to decrease NFκB signaling [@bb0275], [@bb0280], [@bb0285]. As well, androgens decrease expression of *ISG15* and its interacting partners [@bb0190]. Exposure to these hormones in FF may transiently reduce the baseline elevation in inflammatory signaling in mt*BRCA1* cells to the levels of controls by eliminating their relative increase in NFκB activity.

As summarized in [Figure 7](#f0035){ref-type="fig"}*I*, the present study highlights an increase in ISG15 and ISGylation resulting from BRCA1 deficiency and FF exposure. This increase appears to be mediated through increased NFκB signaling due to low levels of functional BRCA1. ISGylation targets multiple proteins, including proteins involved in EGFR and MAPK-ERK1/2 signaling, and has been linked to cancer initiation through increased inflammatory signaling [@bb0220]. Although not tested, increased ISGylation of EGFR-MAPK-ERK1/2 cascade members might contribute to increased pERK1/2 levels associated with decreased BRCA1. It remains to be determined if blocking ISGylation in BRCA1-deficient FTE results in decreased proinflammatory and EGFR signaling and whether this might mitigate the risk for malignant transformation.

The following are the supplementary data related to this article.Supplementary Table S1List of Primers Used for RT-qPCRSupplementary Table S1Supplementary Table S2GO Analyses for Genes Significantly Different in *BRCA1* Mutation Carriers Versus Control Patients at the Three Different Time PointsSupplementary Table S2Supplementary Table S3GO Analyses for Genes Significantly Different in *BRCA2* Mutation Carriers Versus Control Patients at the Three Different Time PointsSupplementary Table S3Supplementary Table S4Significant Gene Sets Altered in mt*BRCA1* Versus Control at C24 Determined by GSEASupplementary Table S4Supplementary Table S5Significant Gene Sets Altered in mt*BRCA1* Versus Control at FC Determined by GSEASupplementary Table S5Supplementary Table S6Top Gene sets Altered in mt*BRCA2* Versus Control at C24 Determined by GSEASupplementary Table S6Supplementary Table S7Top Gene Sets Altered in mt*BRCA2* Versus Control at FC Determined by GSEASupplementary Table S7Supplementary Figure S1Cell viability is not compromised by exposure to follicular fluid. Oviductal cells grown on collagen IV were treated with undiluted follicular fluid or culture medium for 24 hours prior to assessment of cell number by MTT reduction assay. Bars represent mean±SEM. *P*\<.05 as determined by Mann-Whitney *U* test.Supplementary Figure S1Supplementary Figure S2The greatest number of differentially expressed genes relative to control patient samples occurs in mtBRCA1 samples after recovery from follicular fluid exposure (FC). Overlap of statistically significant upregulated (A) or downregulated (B) gene probesets at the three time points in mtBRCA1 or mtBRCA2 samples versus control samples. The number of probesets significantly different based upon one-way ANOVA (*P*\<.05) is indicated.Supplementary Figure S2

We thank Natalie Stickle for help with data analyses.

Funding: This work was supported by the Canadian Institute of Health Research (grant number MOP106679, 2017). J. H. was supported by a Kristi Piia Callum Memorial Fellowship in Ovarian Cancer.

Declarations of Interest: None.

[^1]: Contributed equally to the work.

[^2]: Present affiliation: Trillium Health Partners; Mississauga, ON, Canada.

[^3]: Present affiliation: Beaumont Health System; Royal Oak, MI, USA.

[^4]: *RRSO*, risk-reducing salpingo-oophorectomy; *N/D*, not determined.

[^5]: The average age (±SEM) for *BRCA1* mutation carriers, *BRCA2* mutation carriers, and control patients was 41.7 (±1.7), 43.7 (±2.5), and 49.0 (±2.5) years, respectively \[*F*~(2,\ 21)~=2.698, *P*=.091\].
